<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229241</url>
  </required_header>
  <id_info>
    <org_study_id>2010-019393-32</org_study_id>
    <nct_id>NCT01229241</nct_id>
  </id_info>
  <brief_title>Assessment of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion</brief_title>
  <acronym>LEVOROPI</acronym>
  <official_title>Prospective Randomized Double-blinded Study of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the assessment of the systemic absorption of local anesthetics during
      continuous epidural infusion for postoperative pain control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In literature the systemic toxicity of bupivacaine is widely demonstrated, like the minor
      toxicity of levobupivacaine and ropivacaine at the same anesthetic potency. The are actually
      no studies in humans confronting levobupivacaine and ropivacaine under the aspect of efficacy
      and toxicity.The aim of the study is the assessment of the systemic absorption of local
      anesthetics during continuous epidural infusion for postoperative pain control.

      Primary outcome:

      Assessment of the plasmatic equimolar concentrations of levobupivacaine and ropivacaine
      during continuous epidural infusion

      Secondary outcome:

      Assessment of the safety level of the local anesthetic (major difference between haematic
      concentration of the local anesthetic and neuro-cardiotoxic dose).

      Difference of the analgesic efficacy between levobupivacaine and ropivacaine. Differences in
      collateral effects due to the local anesthetic: hypotension and sensitive block.

      Prospective randomized double-blinded clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of the local anesthetics in study</measure>
    <time_frame>during 60h after surgery</time_frame>
    <description>Assessment of the equivalence of the systemic exposition of levobupivacaine and ropivacaine during 48h continuous epidural infusion with in a range of 15%.Blood samples (8) will be taken for farmacological assessment of local anesthetic plasma concentrations at time (hours) 0,+3h,+6h,+12h,+24h,+48h,+54h,+60h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacological profile of the local anesthetics in study</measure>
    <time_frame>during 60h after surgery</time_frame>
    <description>Assessment of the therapeutic index (plasma concentration of the local anesthetics in study compared to those described in literature to be related to toxic effects).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the to groups (at least 25%) in terms of pain control (1 episode of VAS&gt;4)</measure>
    <time_frame>Pain control (VAS, VASm, rescue dose) during the 72 h postsurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference at least 20% in presentation of collateral effects between the two groups</measure>
    <time_frame>Continuous assessment during the 72 h post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Anesthesia</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>levobupivacaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>local anesthetic</intervention_name>
    <description>postoperative 48h epidural continuous infusion,
ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml
levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml</description>
    <arm_group_label>levobupivacaine</arm_group_label>
    <arm_group_label>ropivacaine</arm_group_label>
    <other_name>Chriocaina</other_name>
    <other_name>Naropina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I or ASA II

          -  Scheduled for major surgery

          -  written informed consent

        Exclusion Criteria:

          -  ASA III, IV

          -  Emergency surgery

          -  Recovery in intensive care unit after surgery

          -  habitual opioid consumption

          -  cognitive or mental alterations

          -  coagulopathy

          -  piastrinemia &lt; 100.000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Allegri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit√† Operativa di Anestesia e Rianimazione - Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Massimo Allegri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>local anesthetic</keyword>
  <keyword>epidural</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>plasmatic concentration</keyword>
  <keyword>epidural continuous infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

